6th Annual Future of Clinical Trials

Jacob Fleming Conferences26 - 27 October 2010, Vienna, Austria.
Leading Pharmaceutical players understand, how to complete trials with greater levels of cost-efficiency, timelines and success. Reveal, how to tailor clinical trials to the needs of the patients. Discuss the innovative methods of motivating patients and physicians. Learn from first hand experience, how to optimize patient recruitment & retention, and explore the patient pool in Russia and Southeastern Europe. Achieve the competitive advantage through increased partnering with academic centres of excellence, patient organizations and CROs.

Discuss with leading Pharma companies, what is the future of clinical trials & how to be prepared to succeed.

Key speakers:

  • Senior Vice President Global Clinical Operations, MerckSerono, Switzerland
  • Vice President Medical Affairs Global Diabetes Division, Sanofi Aventis, France
  • Deputy Head of Global Clinical Development Metabolism, Development Sub-Team Leader Dalcetrapib, Roche, Swizterland
  • VP R&D Science Policy, AstraZeneca, UK
  • Head Clinical Research, Novartis, Switzerland
  • Head Clinical Research, Novo Nordisk, Russia
  • Project Officer, VSOP, The Netherlands
  • Head of Biostatistics & Data Management, Global Clinical R&D, GSK Biologicals, Belgium
  • European AIDS Treatment Group (EATG), Germany
  • Chief Medical Officer Southern Europem, Novartis Vaccines & Diagnostics, Italy

Key topics:

  • New approaches to conducting clinical trials in a current dynamic and competitive environment
  • Examine key recruiting trends in Europe & Asia – exploit the patient pool and trials potential in the Southeastern Europe, Russia & Asian countries
  • Achieve competitive advantage through increased partnerships with academic centres of excellence, patient organizations & CROs
  • Gain first-hand information on PatientPartner project – how to establish partnership between stakeholders to the benefit of clinical trials and the treatment of patients in the future
  • Explore innovative methods of motivating investigators and patients
  • Understand the recent developments in the regulatory & legal environment
  • Best practices in designing a study protocol

Who should attend:
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Clinical Development, Clinical Operations, Clinical Trials, Clinical Research, Patient Recruitment, Patient Retention, Site Management, Clinical Outsourcing, Sourcing Strategies, Medical Affairs, Contract Outsourcing, Clinical Strategy, Clinical Project Management, Regulatory Affairs, Clinical Research Associates, Clinical Research Organizations.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/6th-annual-future-of-clinical-trials?partner=worldpharmanews

About Jacob Fleming Group
Jacob Fleming Conferences are carefully designed to provide key strategic business information and the best networking opportunities for the participants. Our business to business conferences are highly interactive events with a limited number of delegates from specialized industry sectors. For each conference Jacob Fleming brings together selected senior level executives who become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Delivering insulin in a pill

Given the choice of taking a pill or injecting oneself with a needle, most of us would opt to regulate a chronic health condition by swallowing a pill. But for millions o...

Probiotics can protect the skeletons of older wome…

For the first time in the world, researchers at the University of Gothenburg, Sweden, have demonstrated that probiotics, dietary supplements with health-promoting bacteri...

Alzheimer's breakthrough: Brain metals that may dr…

Alzheimer's disease could be better treated, thanks to a breakthrough discovery of the properties of the metals in the brain involved in the progression of the neurodegen...

Can aspirin treat Alzheimer's?

A regimen of low-dose aspirin potentially may reduce plaques in the brain, which will reduce Alzheimer's disease pathology and protect memory, according to neurological r...

FDA approves first drug comprised of an active ing…

The U.S. Food and Drug Administration today approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms o...

In mice, stem cells seem to work in fighting obesi…

Obesity is an increasing global health problem associated with several comorbidities and a high risk of mortality. A wide spectrum of interventions has been proposed for ...

FDA takes steps to foster greater efficiency in bi…

Today, the agency withdrew the draft guidance, "Statistical Approaches to Evaluate Analytical Similarity," issued in September 2017. The draft guidance, if finalized as w...

Research shows how a moderate dose of alcohol prot…

For at least 20 years, research has shown that for many people, moderate consumption of alcohol can protect the heart, but the reason for this is poorly understood. A stu...

'Kiss of death' cancer

It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negativ...

Some existing anti-cancer drugs may act in part by…

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti...

Novartis Clear about Psoriasis survey data highlig…

Novartis announced today the publication of global Clear about Psoriasis survey data in the Journal of the European Academy of Dermatology and Venereology[1]. The publica...

Poliovirus therapy for recurrent glioblastoma has …

A genetically modified poliovirus therapy developed at Duke Cancer Institute shows significantly improved long-term survival for patients with recurrent glioblastoma, wit...